440 related articles for article (PubMed ID: 23562987)
1. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.
Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Kalstad S; Rødevand E; Mikkelsen K; Lexberg AS; Kvien TK
Ann Rheum Dis; 2013 Nov; 72(11):1840-4. PubMed ID: 23562987
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register.
Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Rødevand E; Koldingsnes W; Kaufmann C; Kvien TK
Ann Rheum Dis; 2011 Jan; 70(1):157-63. PubMed ID: 21062852
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.
Chatzidionysiou K; Askling J; Eriksson J; Kristensen LE; van Vollenhoven R;
Ann Rheum Dis; 2015 May; 74(5):890-6. PubMed ID: 24431398
[TBL] [Abstract][Full Text] [Related]
4. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry.
Glintborg B; Østergaard M; Krogh NS; Tarp U; Manilo N; Loft AG; Hansen A; Schlemmer A; Fana V; Lindegaard HM; Nordin H; Rasmussen C; Ejstrup L; Jensen DV; Petersen PM; Hetland ML
Ann Rheum Dis; 2013 Jul; 72(7):1149-55. PubMed ID: 22941767
[TBL] [Abstract][Full Text] [Related]
5. Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers.
Lequerré T; Farran É; Ménard JF; Kozyreff-Meurice M; Vandhuick T; Tharasse C; Pouplin S; Daragon A; Le Loët X; Varin R; Vittecoq O
Joint Bone Spine; 2015 Oct; 82(5):330-7. PubMed ID: 25864942
[TBL] [Abstract][Full Text] [Related]
6. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.
Glintborg B; Ostergaard M; Krogh NS; Andersen MD; Tarp U; Loft AG; Lindegaard HM; Holland-Fischer M; Nordin H; Jensen DV; Olsen CH; Hetland ML
Arthritis Rheum; 2013 May; 65(5):1213-23. PubMed ID: 23460467
[TBL] [Abstract][Full Text] [Related]
7. Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis.
Chandran V; Shen H; Pollock RA; Pellett FJ; Carty A; Cook RJ; Gladman DD
J Rheumatol; 2013 Jun; 40(6):866-71. PubMed ID: 23637322
[TBL] [Abstract][Full Text] [Related]
8. Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors.
Finzel S; Kraus S; Schmidt S; Hueber A; Rech J; Engelke K; Englbrecht M; Schett G
Ann Rheum Dis; 2013 Jul; 72(7):1176-81. PubMed ID: 22915620
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden.
Kristensen LE; Lie E; Jacobsson LT; Christensen R; Mease PJ; Bliddal H; Geborek P
J Rheumatol; 2016 Jan; 43(1):81-7. PubMed ID: 26628604
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.
Ritchlin C; Rahman P; Kavanaugh A; McInnes IB; Puig L; Li S; Wang Y; Shen YK; Doyle MK; Mendelsohn AM; Gottlieb AB;
Ann Rheum Dis; 2014 Jun; 73(6):990-9. PubMed ID: 24482301
[TBL] [Abstract][Full Text] [Related]
11. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.
Iannone F; Lopriore S; Bucci R; Scioscia C; Anelli MG; Notarnicola A; Lapadula G
Scand J Rheumatol; 2015 May; 44(3):192-9. PubMed ID: 25564882
[TBL] [Abstract][Full Text] [Related]
12. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.
Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Lexberg AS; Rødevand E; Kalstad S; Mikkelsen K; Kvien TK
Ann Rheum Dis; 2014 Jan; 73(1):132-7. PubMed ID: 23291385
[TBL] [Abstract][Full Text] [Related]
13. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.
Jamnitski A; Bartelds GM; Nurmohamed MT; van Schouwenburg PA; van Schaardenburg D; Stapel SO; Dijkmans BA; Aarden L; Wolbink GJ
Ann Rheum Dis; 2011 Feb; 70(2):284-8. PubMed ID: 21068090
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
Akiyama M; Kaneko Y; Kondo H; Takeuchi T
Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
[TBL] [Abstract][Full Text] [Related]
15. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry.
Greenberg JD; Reed G; Decktor D; Harrold L; Furst D; Gibofsky A; Dehoratius R; Kishimoto M; Kremer JM;
Ann Rheum Dis; 2012 Jul; 71(7):1134-42. PubMed ID: 22294625
[TBL] [Abstract][Full Text] [Related]
16. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
[TBL] [Abstract][Full Text] [Related]
17. Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy.
Wei W; Knapp K; Wang L; Chen CI; Craig GL; Ferguson K; Schwartzman S
Adv Ther; 2017 Aug; 34(8):1936-1952. PubMed ID: 28674959
[TBL] [Abstract][Full Text] [Related]
18. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.
Conti F; Ceccarelli F; Marocchi E; Magrini L; Spinelli FR; Spadaro A; Scrivo R; Valesini G
Ann Rheum Dis; 2007 Oct; 66(10):1393-7. PubMed ID: 17613555
[TBL] [Abstract][Full Text] [Related]
19. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?
Hjardem E; Østergaard M; Pødenphant J; Tarp U; Andersen LS; Bing J; Peen E; Lindegaard HM; Ringsdal VS; Rødgaard A; Skøt J; Hansen A; Mogensen HH; Unkerskov J; Hetland ML
Ann Rheum Dis; 2007 Sep; 66(9):1184-9. PubMed ID: 17389656
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of rheumatic diseases: current status and future prospective. Topics: III. Biological drugs; 1. TNF inhibitors].
Amano K
Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):2966-71. PubMed ID: 22175139
[No Abstract] [Full Text] [Related]
[Next] [New Search]
